Ratti M, Orlandi E, Hahne J, Vecchia S, Citterio C, Anselmi E
Biomedicines. 2023; 11(10).
PMID: 37893023
PMC: 10603875.
DOI: 10.3390/biomedicines11102650.
Lim E, Lim S, Tan K, Sathiya M, Cheng W, Lai K
Life (Basel). 2022; 12(7).
PMID: 35888106
PMC: 9316931.
DOI: 10.3390/life12071018.
Szymczyk J, Sluzalska K, Materla I, Opalinski L, Otlewski J, Zakrzewska M
Cancers (Basel). 2021; 13(22).
PMID: 34830951
PMC: 8616288.
DOI: 10.3390/cancers13225796.
Kim J, Jeong S, Jang H, Park S, Kim H
Front Oncol. 2021; 11:762528.
PMID: 34737965
PMC: 8560792.
DOI: 10.3389/fonc.2021.762528.
Peng T, Sun Y, Lv Z, Zhang Z, Su Q, Wu H
Sci Rep. 2021; 11(1):1373.
PMID: 33446698
PMC: 7809464.
DOI: 10.1038/s41598-020-80146-y.
An updated meta-analysis of the association between fibroblast growth factor receptor 4 polymorphisms and susceptibility to cancer.
Moazeni-Roodi A, Sarabandi S, Karami S, Hashemi M, Ghavami S
Biosci Rep. 2020; 40(10).
PMID: 33017009
PMC: 7584815.
DOI: 10.1042/BSR20192051.
FGFR4 regulates tumor subtype differentiation in luminal breast cancer and metastatic disease.
Garcia-Recio S, Thennavan A, East M, Parker J, Cejalvo J, Garay J
J Clin Invest. 2020; 130(9):4871-4887.
PMID: 32573490
PMC: 7456247.
DOI: 10.1172/JCI130323.
FGF19- Signaling in Hepatocellular Carcinoma.
Raja A, Park I, Haq F, Ahn S
Cells. 2019; 8(6).
PMID: 31167419
PMC: 6627123.
DOI: 10.3390/cells8060536.
Blocking FGFR4 exerts distinct anti-tumorigenic effects in esophageal squamous cell carcinoma.
Xin Z, Song X, Jiang B, GongSun X, Song L, Qin Q
Thorac Cancer. 2018; 9(12):1687-1698.
PMID: 30267473
PMC: 6275831.
DOI: 10.1111/1759-7714.12883.
Functional FGFR4 Gly388Arg polymorphism contributes to cancer susceptibility: Evidence from meta-analysis.
Xiong S, Ma J, Feng F, Fu W, Shu S, Ma T
Oncotarget. 2017; 8(15):25300-25309.
PMID: 28445975
PMC: 5421931.
DOI: 10.18632/oncotarget.15811.
Arg388 Is Correlated with Poor Survival in Resected Colon Cancer Promoting Epithelial to Mesenchymal Transition.
Cho S, Hong C, Kim H, Shin M, Kim K, Shim H
Cancer Res Treat. 2016; 49(3):766-777.
PMID: 27857023
PMC: 5512371.
DOI: 10.4143/crt.2016.457.
Fibroblast growth factor receptor 4 (FGFR4) and fibroblast growth factor 19 (FGF19) autocrine enhance breast cancer cells survival.
Tiong K, Tan B, Choo H, Chung F, Hii L, Tan S
Oncotarget. 2016; 7(36):57633-57650.
PMID: 27192118
PMC: 5295378.
DOI: 10.18632/oncotarget.9328.
High Expression of FGFR4 Enhances Tumor Growth and Metastasis in Nasopharyngeal Carcinoma.
Shi S, Li X, You B, Shan Y, Cao X, You Y
J Cancer. 2015; 6(12):1245-54.
PMID: 26535066
PMC: 4622855.
DOI: 10.7150/jca.12825.
Association of FGFR3 and FGFR4 gene polymorphisms with breast cancer in Chinese women of Heilongjiang province.
Jiang Y, Sun S, Wei W, Ren Y, Liu J, Pang D
Oncotarget. 2015; 6(32):34023-9.
PMID: 26431494
PMC: 4741823.
DOI: 10.18632/oncotarget.5850.
Fibroblast Growth Factor Receptor Family Members as Prognostic Biomarkers in Head and Neck Squamous Cell Carcinoma: A Systematic Review.
Ipenburg N, Koole K, Liem K, van Kempen P, Koole R, van Diest P
Target Oncol. 2015; 11(1):17-27.
PMID: 26115874
PMC: 4759209.
DOI: 10.1007/s11523-015-0374-9.
Is fibroblast growth factor receptor 4 a suitable target of cancer therapy?.
Heinzle C, Erdem Z, Paur J, Grasl-Kraupp B, Holzmann K, Grusch M
Curr Pharm Des. 2013; 20(17):2881-98.
PMID: 23944363
PMC: 5453246.
DOI: 10.2174/13816128113199990594.
Fibroblast growth factor receptor 4 Gly388Arg polymorphism in Chinese gastric cancer patients.
Shen Y, Lu Y, Shen D, Liu Y, Su X, Zhu G
World J Gastroenterol. 2013; 19(28):4568-75.
PMID: 23901234
PMC: 3725383.
DOI: 10.3748/wjg.v19.i28.4568.
Functional roles of fibroblast growth factor receptors (FGFRs) signaling in human cancers.
Tiong K, Mah L, Leong C
Apoptosis. 2013; 18(12):1447-68.
PMID: 23900974
PMC: 3825415.
DOI: 10.1007/s10495-013-0886-7.
FGFR4 role in epithelial-mesenchymal transition and its therapeutic value in colorectal cancer.
Pelaez-Garcia A, Barderas R, Torres S, Hernandez-Varas P, Teixido J, Bonilla F
PLoS One. 2013; 8(5):e63695.
PMID: 23696849
PMC: 3655941.
DOI: 10.1371/journal.pone.0063695.
FGFR4 genetic polymorphisms determine the chemotherapy response of Chinese patients with non-small cell lung cancer.
Fang H, Tian G, Zhou L, Zhou H, Fang Y
Acta Pharmacol Sin. 2013; 34(4):549-54.
PMID: 23524567
PMC: 4002793.
DOI: 10.1038/aps.2012.206.